2021 High quality Sofosbuvir - Levetiracetam LEV CAS 102767-28-2 API USP EP Standard High Purity – Ruifu

Manufacturer Supply with High Purity and Stable Quality
Chemical Name: Levetiracetam
CAS: 102767-28-2
API USP/EP Standard High Purity
A Third-generation Antiepileptic Drug
API High Quality, Commercial Production

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Levetiracetam, a derivative of pilacetam, is a novel third-generation antiepileptic drug approved by the US FDA in 1999. It was initially used for the adjunctive treatment of partial seizures in adults. In 2005, Levetiracetam was approved in oral tablets and solutions for the adjunctive treatment of partial seizures in children aged 4 years and older. It is mainly used for the additive treatment of partial seizures in adults and children over 4 years old, and can also be used only for partial seizures and systemic seizures in adults. It also has certain curative effect on myoclonic epilepsy in teenagers, refractory epilepsy, absent epilepsy in children and persistent epilepsy.LEV has been reported to improve cognitive function in patients with epilepsy, and can also be used for myoclonus caused by other causes (such as encephalitis and cerebral hypoxia).

Levetiracetam is a relatively unique anticonvulsant that is typically used in combination with other antiepileptic medications for partial onset seizures. Levetiracetam is an antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+-dependent Cl-/HCO3- exchange.